enGene Holdings has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $200 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, enGene Holdings is raising $200,000,000.00 in new funding. About enGene Holdings: enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Gurin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
To learn more about enGene Holdings, visit http://engene.com/
Contact:
Jason Hanson, Chief Executive Officer
514-332-4888
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.